List of works - Joan Carles Galcerán

5-fluorouracil, ifosfamide and mitomycin (FIM) combination for pancreatic-biliary tumors

scientific article published on 01 February 1991

A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.

scientific article published on 22 October 2015

A phase II study of days 1 and 8 cisplatin and recombinant alpha-2B interferon in advanced non-small cell lung cancer

scientific article published on 01 May 1991

A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.

scientific article published on July 2010

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3

scientific article published on 16 January 2015

Abiraterone in metastatic prostate cancer without previous chemotherapy

scientific article published on 10 January 2013

Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).

scientific article published on 15 February 2010

Acute aortic dissection during sorafenib-containing therapy

scientific article published on 25 October 2009

Adjuvant therapy with cetuximab for locally advanced squamous cell carcinoma of the oropharynx: results from a randomized, phase II prospective trial

scientific article published on 05 October 2012

An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA)

scientific article published on 16 September 2018

Anal carcinoma: a 14 year experience

scientific article published on 01 January 1997

BRAF V600E and KRAS G12S mutations in peripheral nerve sheath tumours

scientific article published on 27 November 2012

Bilateral testicular germ cell tumours: a single hospital experience

scientific article published on 01 April 2010

Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.

scientific article published on 25 June 2013

Calcification of lymph node metastases from prostate carcinoma after hormonal treatment: a case report

scientific article published on 01 October 1997

Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function

scientific article

Castration-resistant metastatic prostate cancer: current status and treatment possibilities.

scientific article published on March 2012

Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma.

scientific article

Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function

scientific article

Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients

scientific article published on 01 January 1992

Do patients with metastatic urothelial carcinoma benefit from docetaxel as second-line chemotherapy?

scientific article published on 20 April 2013

E400P in advanced seminoma of good prognosis according to the international germ cell cancer collaborative group (IGCCCG) classification: the Spanish Germ Cell Cancer Group experience

scientific article published in April 2001

Eccrine porocarcinoma presenting with scrotal lymphedema: a case report and review of systemic treatment

scientific article published on 20 January 2010

Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial.

scientific article

Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer

scientific article published on 04 July 2015

Emerging therapies for urothelial cancer.

scientific article

Enzalutamide in metastatic prostate cancer before chemotherapy

scientific article published in June 2014

Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis

scientific article published on 26 August 2016

Evaluation of patients with metastatic renal cell carcinoma after failure of first-line treatment.

scientific article published on September 2012

Expression of cyclooxygenase-2 mRNA in peripheral blood of head and neck cancer patients and in healthy controls. A pilot study.

scientific article published on January 2007

Feasiblity study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function

scientific article published on 01 October 2006

Free Testosterone During Androgen Deprivation Therapy Predicts Castration-Resistant Progression Better Than Total Testosterone.

scientific article

Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy

scientific article

Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer

scientific article published on 01 August 2007

Gemcitabine/carboplatin in advanced urothelial cancer.

scientific article

Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer

scientific article

Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.

scientific article

Her-2/neu expression in prostate cancer: a dynamic process?

scientific article published on 01 July 2004

Hormonal changes after localized prostate cancer treatment. Comparison between external beam radiation therapy and radical prostatectomy

scientific article published on 17 May 2016

Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma

scientific article published on 24 January 2014

Impact of PSA implementation and combined radiation and hormonal therapy (RT+HT) on outcome of prostate cancer patients

scientific article published on 20 July 2009

Management and interpretation of novel toxicities of molecular targeted therapies: renal toxicities.

scientific article published on September 2009

Metabolic syndrome increases the risk of aggressive prostate cancer detection

scientific article published on 9 August 2012

Molecular basis for the treatment of renal cell carcinoma.

scientific article published on January 2010

Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma

scientific article published on 01 June 2003

Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer

scientific article published on 01 December 1993

Non-metastatic castration-resistant prostate cancer (CPRCM0), an old scenario with renewed clinical interest

scientific article published on 25 May 2014

Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors

scientific article published on 7 May 2017

Phase I study of mitonafide in 120 hour continuous infusion in non-small cell lung cancer

scientific article published on 01 August 1992

Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.

scientific article

Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.

scientific article

Phase II clinical trial of PM00104 (Zalypsis(®)) in urothelial carcinoma patients progressing after first-line platinum-based regimen

scientific article published on 26 February 2014

Phase II feasibility study of high dose epirubicin plus etoposide and cisplatin (HDEEC) regimen in small cell lung cancer

scientific article

Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer

scientific article

Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients.

scientific article

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.

scientific article published on 21 March 2011

Phase II study of vinorelbine and estramustine in combination with conformational radiotherapy for patients with high-risk prostate cancer.

scientific article

Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer

scientific article published on 7 November 2005

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract

scientific article

Predictive modelling in hormone-refractory prostate cancer (HRPC).

scientific article published in February 2009

Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.

scientific article published on December 2006

Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.

scientific article

Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG)

scientific article published on 10 September 2014

Prognostic implications of P-glycoprotein, epidermal growth factor receptor and transforming growth factor alpha

scientific article published on 01 July 1996

Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study.

scientific article published on 15 March 2010

RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas.

scientific article published on 19 October 2015

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial

scientific article

Randomized trial for the control of acute vomiting in cisplatin-treated patients: high-dose metoclopramide with dexamethasone and lorazepam as adjuncts versus high-dose alizapride plus dexamethasone and lorazepam. Study of the incidence of delayed e

scientific article published on 01 January 1991

Relationship between radiation-induced apoptosis of T lymphocytes and chronic toxicity in patients with prostate cancer treated by radiation therapy: a prospective study

scientific article published on 01 April 2014

Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients.

scientific article

Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study.

scientific article published on 31 October 2005

Role of immunotherapy in castration-resistant prostate cancer (CRPC).

scientific article published on 12 April 2013

Role of serum cholesterol and statin use in the risk of prostate cancer detection and tumor aggressiveness.

scientific article

SEOM clinical guidelines for the treatment of invasive bladder cancer

scientific article published on 01 August 2011

Schwannomas, benign tumors with a senescent phenotype

scientific article published on 12 November 2013

Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model.

scientific article published on 24 October 2015

Second-line Chemotherapy in Older Patients With Metastatic Urothelial Carcinoma: Pooled Analysis of 10 Second-line Studies

scientific article published on 22 December 2016

Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223.

scientific article published on 2 November 2017

Sequential combination of methotrexate (MTX), 5-fluorouracil (FU), and high-dose folinic acid (FA) in advanced colorectal cancer: double biochemical modulation?

scientific article

Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer

scientific article

Sweet's syndrome and malignancy: a case associated with multiple oral squamous-cell carcinoma

scientific article published on 01 January 1996

Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope

scientific article

Therapeutic challenge for Isospora belli enteritis in an AIDS patient who developed Lyell syndrome after co-trimoxazole therapy.

scientific article published in February 1989

Unveiling changes in the landscape of patient populations in cancer early drug development

scientific article

Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).

scientific article published on 6 March 2014

Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer

scientific article published on 08 June 2015

Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study

scientific article published on 30 May 2013

Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study

scientific article published on 23 October 2007

[Atypical localization of synovial sarcoma]

scientific article published on 01 June 1993

[Carcinoma of unknown origin. Diagnostic study of 48 cases and its clinical yield]

scientific article published on 01 February 1989

[Castration-resistant prostate cancer: where are we going?]

scientific article published on 19 December 2011

[Colorimetric determination of starch]

scientific article published on 01 January 1954

[Recomendations on the management of controversies in advanced castrate-resistant prostate cancer]

scientific article published on 19 September 2012

[The description of a new cellular type, Pinocchio cells, induced during the treatment of solid tumors with interleukin-2]

scientific article published on 01 October 1990

List of works by Joan Carles Galcerán

5-fluorouracil, ifosfamide and mitomycin (FIM) combination for pancreatic-biliary tumors

A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.

A phase II study of days 1 and 8 cisplatin and recombinant alpha-2B interferon in advanced non-small cell lung cancer

A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3

Abiraterone in metastatic prostate cancer without previous chemotherapy

Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).

Acute aortic dissection during sorafenib-containing therapy

Adjuvant therapy with cetuximab for locally advanced squamous cell carcinoma of the oropharynx: results from a randomized, phase II prospective trial

An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA)

Anal carcinoma: a 14 year experience

BRAF V600E and KRAS G12S mutations in peripheral nerve sheath tumours

Bilateral testicular germ cell tumours: a single hospital experience

Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.

Calcification of lymph node metastases from prostate carcinoma after hormonal treatment: a case report

Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function

Castration-resistant metastatic prostate cancer: current status and treatment possibilities.

Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma.

Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function

Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients

Do patients with metastatic urothelial carcinoma benefit from docetaxel as second-line chemotherapy?

E400P in advanced seminoma of good prognosis according to the international germ cell cancer collaborative group (IGCCCG) classification: the Spanish Germ Cell Cancer Group experience

Eccrine porocarcinoma presenting with scrotal lymphedema: a case report and review of systemic treatment

Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial.

Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer

Emerging therapies for urothelial cancer.

Enzalutamide in metastatic prostate cancer before chemotherapy

Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis

Evaluation of patients with metastatic renal cell carcinoma after failure of first-line treatment.

Expression of cyclooxygenase-2 mRNA in peripheral blood of head and neck cancer patients and in healthy controls. A pilot study.

Feasiblity study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function

Free Testosterone During Androgen Deprivation Therapy Predicts Castration-Resistant Progression Better Than Total Testosterone.

Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy

Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer

Gemcitabine/carboplatin in advanced urothelial cancer.

Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer

Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.

Her-2/neu expression in prostate cancer: a dynamic process?

Hormonal changes after localized prostate cancer treatment. Comparison between external beam radiation therapy and radical prostatectomy

Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma

Impact of PSA implementation and combined radiation and hormonal therapy (RT+HT) on outcome of prostate cancer patients

Management and interpretation of novel toxicities of molecular targeted therapies: renal toxicities.

Metabolic syndrome increases the risk of aggressive prostate cancer detection

Molecular basis for the treatment of renal cell carcinoma.

Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma

Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer

Non-metastatic castration-resistant prostate cancer (CPRCM0), an old scenario with renewed clinical interest

Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors

Phase I study of mitonafide in 120 hour continuous infusion in non-small cell lung cancer

Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.

Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.

Phase II clinical trial of PM00104 (Zalypsis(®)) in urothelial carcinoma patients progressing after first-line platinum-based regimen

Phase II feasibility study of high dose epirubicin plus etoposide and cisplatin (HDEEC) regimen in small cell lung cancer

Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer

Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients.

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.

Phase II study of vinorelbine and estramustine in combination with conformational radiotherapy for patients with high-risk prostate cancer.

Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract

Predictive modelling in hormone-refractory prostate cancer (HRPC).

Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.

Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.

Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG)

Prognostic implications of P-glycoprotein, epidermal growth factor receptor and transforming growth factor alpha

Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study.

RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas.

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial

Randomized trial for the control of acute vomiting in cisplatin-treated patients: high-dose metoclopramide with dexamethasone and lorazepam as adjuncts versus high-dose alizapride plus dexamethasone and lorazepam. Study of the incidence of delayed e

Relationship between radiation-induced apoptosis of T lymphocytes and chronic toxicity in patients with prostate cancer treated by radiation therapy: a prospective study

Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients.

Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study.

Role of immunotherapy in castration-resistant prostate cancer (CRPC).

Role of serum cholesterol and statin use in the risk of prostate cancer detection and tumor aggressiveness.

SEOM clinical guidelines for the treatment of invasive bladder cancer

Schwannomas, benign tumors with a senescent phenotype

Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model.

Second-line Chemotherapy in Older Patients With Metastatic Urothelial Carcinoma: Pooled Analysis of 10 Second-line Studies

Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223.

Sequential combination of methotrexate (MTX), 5-fluorouracil (FU), and high-dose folinic acid (FA) in advanced colorectal cancer: double biochemical modulation?